Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo
Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...
Saved in:
Main Authors: | Shunsuke Wada (Author), Satoshi Obika (Author), Masa-Aki Shibata (Author), Tsuyoshi Yamamoto (Author), Moeka Nakatani (Author), Tetsuji Yamaoka (Author), Hidetaka Torigoe (Author), Mariko Harada-Shiba (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
by: Tsuyoshi Yamamoto, et al.
Published: (2012) -
Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4' -BNA/LNA with 9-(aminoethoxy)phenoxazine
by: Taiki Matsubayashi, et al.
Published: (2024) -
Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine
by: Taiki Matsubayashi, et al.
Published: (2024) -
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
by: Tsuyoshi Yamamoto, et al.
Published: (2021) -
Targeting LDL Cholesterol With LNA
by: Arthur M Krieg
Published: (2012)